BACE1 and Alzheimer disease: Furthermore, there is emerging evidence that BACE1 inhibitors may be potentially interesting tools in the management of AD (Rueeger et al., 2021), while the inhibition of GSK3B can reduce the phosphorylation of Tau and the conversion of APP to Aβ.